

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in understanding and managing... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/9-685/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/9-685" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in understanding and managing pediatric rhabdomyosarcoma" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in understanding and managing pediatric rhabdomyosarcoma.">
            <meta name="og:description" content="Read the latest article version by Jessica Gartrell, Alberto Pappo, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="24777">
            <meta name="article-id" content="22451">
            <meta name="dc.title" content="Recent advances in understanding and managing pediatric rhabdomyosarcoma">
            <meta name="dc.description" content="Rhabdomyosarcoma (RMS) is a high-grade malignant neoplasm, with a morphologic appearance mimicking that of developing skeletal muscle. Over the last 30 years, patient outcomes have improved with the incorporation of multimodal therapies, including chemotherapy, radiation therapy, and surgery. The overall cure rates exceed 70%, with patients who have low-, intermediate-, and high-risk disease experiencing long-term survival rates of &amp;gt;90%, 70%, and &amp;lt;30%, respectively. Historically, RMS was classified according to histology; however, recent advances have revealed new molecular subgroups that allow us to more accurately identify high-, intermediate-, and low-risk disease. In this review, we discuss recent advances made in understanding RMS tumor biology and propose how this understanding can drive a new classification system that can guide clinical approaches for treatment de-escalation in patients with expected favorable outcomes and escalation for those with expected poor outcomes.">
            <meta name="dc.subject" content="rhabdomyosarcoma, pediatric, sarcoma">
            <meta name="dc.creator" content="Gartrell, Jessica">
            <meta name="dc.creator" content="Pappo, Alberto">
            <meta name="dc.date" content="2020/07/08">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.22451.1">
            <meta name="dc.source" content="F1000Research 2020 9:685">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="rhabdomyosarcoma">
            <meta name="prism.keyword" content="pediatric">
            <meta name="prism.keyword" content="sarcoma">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2020/07/08">
            <meta name="prism.volume" content="9">
            <meta name="prism.number" content="685">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.22451.1">
            <meta name="prism.url" content="https://f1000research.com/articles/9-685">
            <meta name="citation_title" content="Recent advances in understanding and managing pediatric rhabdomyosarcoma">
            <meta name="citation_abstract" content="Rhabdomyosarcoma (RMS) is a high-grade malignant neoplasm, with a morphologic appearance mimicking that of developing skeletal muscle. Over the last 30 years, patient outcomes have improved with the incorporation of multimodal therapies, including chemotherapy, radiation therapy, and surgery. The overall cure rates exceed 70%, with patients who have low-, intermediate-, and high-risk disease experiencing long-term survival rates of &amp;gt;90%, 70%, and &amp;lt;30%, respectively. Historically, RMS was classified according to histology; however, recent advances have revealed new molecular subgroups that allow us to more accurately identify high-, intermediate-, and low-risk disease. In this review, we discuss recent advances made in understanding RMS tumor biology and propose how this understanding can drive a new classification system that can guide clinical approaches for treatment de-escalation in patients with expected favorable outcomes and escalation for those with expected poor outcomes.">
            <meta name="citation_description" content="Rhabdomyosarcoma (RMS) is a high-grade malignant neoplasm, with a morphologic appearance mimicking that of developing skeletal muscle. Over the last 30 years, patient outcomes have improved with the incorporation of multimodal therapies, including chemotherapy, radiation therapy, and surgery. The overall cure rates exceed 70%, with patients who have low-, intermediate-, and high-risk disease experiencing long-term survival rates of &amp;gt;90%, 70%, and &amp;lt;30%, respectively. Historically, RMS was classified according to histology; however, recent advances have revealed new molecular subgroups that allow us to more accurately identify high-, intermediate-, and low-risk disease. In this review, we discuss recent advances made in understanding RMS tumor biology and propose how this understanding can drive a new classification system that can guide clinical approaches for treatment de-escalation in patients with expected favorable outcomes and escalation for those with expected poor outcomes.">
            <meta name="citation_keywords" content="rhabdomyosarcoma, pediatric, sarcoma">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Jessica Gartrell">
            <meta name="citation_author_institution" content="Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA">
            <meta name="citation_author" content="Alberto Pappo">
            <meta name="citation_author_institution" content="Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA">
            <meta name="citation_publication_date" content="2020/07/08">
            <meta name="citation_volume" content="9">
            <meta name="citation_publication_number" content="685">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.22451.1">
            <meta name="citation_firstpage" content="685">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/9-685/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/9-685.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=24777 /> <input type=hidden id=articleId name=articleId value=22451 /> <input type=hidden id=xmlUrl value="/articles/9-685/v1/xml"/> <input type=hidden id=xmlFileName value="-9-685-v1.xml"> <input type=hidden id=article_uuid value=9edfe0dd-64ee-41f3-88bf-a03a8493c1de /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in understanding and managing pediatric rhabdomyosarcoma"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.22451.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.22451.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/9-685"
  },
  "headline": "Recent advances in understanding and managing pediatric rhabdomyosarcoma",
  "datePublished": "2020-07-08T13:19:26",
  "dateModified": "2020-07-08T13:19:26",
  "author": [
    {
      "@type": "Person",
      "name": "Jessica Gartrell"
    },    {
      "@type": "Person",
      "name": "Alberto Pappo"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Rhabdomyosarcoma (RMS) is a high-grade malignant neoplasm, with a morphologic appearance mimicking that of developing skeletal muscle. Over the last 30 years, patient outcomes have improved with the incorporation of multimodal therapies, including chemotherapy, radiation therapy, and surgery. The overall cure rates exceed 70%, with patients who have low-, intermediate-, and high-risk disease experiencing long-term survival rates of &amp;gt;90%, 70%, and &amp;lt;30%, respectively. Historically, RMS was classified according to histology; however, recent advances have revealed new molecular subgroups that allow us to more accurately identify high-, intermediate-, and low-risk disease. In this review, we discuss recent advances made in understanding RMS tumor biology and propose how this understanding can drive a new classification system that can guide clinical approaches for treatment de-escalation in patients with expected favorable outcomes and escalation for those with expected poor outcomes."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/9-685",
            "name": "Recent advances in understanding and managing pediatric rhabdomyosarcoma"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in understanding and managing pediatric rhabdomyosarcoma </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=24777 data-id=22451 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22451.1" data-recommended="" data-doi="10.12688/f1000research.22451.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/9-685/v1/pdf?article_uuid=9edfe0dd-64ee-41f3-88bf-a03a8493c1de" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-22451-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-22451-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-22451-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Gartrell J and Pappo A. Recent advances in understanding and managing pediatric rhabdomyosarcoma [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):685 (<a class=new-orange href="https://doi.org/10.12688/f1000research.22451.1" target=_blank>https://doi.org/10.12688/f1000research.22451.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-22451-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=22451 id=track-article-signin-22451 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22451?target=/articles/9-685">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24777 /> <input name=articleId type=hidden value=22451 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in understanding and managing pediatric rhabdomyosarcoma</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Jessica Gartrell<a href="https://orcid.org/0000-0002-1722-2924" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-1722-2924</div>,&nbsp;</span><span class=""><a href="mailto:alberto.pappo@stjude.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Alberto Pappo</span></a></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Jessica Gartrell<a href="http://orcid.org/0000-0002-1722-2924" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-1722-2924</div>,&nbsp;</span><span class=""><a href="mailto:alberto.pappo@stjude.org" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Alberto Pappo</span></a></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 08 Jul 2020 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.22451.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA<br/> <p> <div class=margin-bottom> Jessica Gartrell <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Alberto Pappo <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=64354-66053></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=70790-66052></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=70791-66054></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Rhabdomyosarcoma (RMS) is a high-grade malignant neoplasm, with a morphologic appearance mimicking that of developing skeletal muscle. Over the last 30 years, patient outcomes have improved with the incorporation of multimodal therapies, including chemotherapy, radiation therapy, and surgery. The overall cure rates exceed 70%, with patients who have low-, intermediate-, and high-risk disease experiencing long-term survival rates of &gt;90%, 70%, and &lt;30%, respectively. Historically, RMS was classified according to histology; however, recent advances have revealed new molecular subgroups that allow us to more accurately identify high-, intermediate-, and low-risk disease. In this review, we discuss recent advances made in understanding RMS tumor biology and propose how this understanding can drive a new classification system that can guide clinical approaches for treatment de-escalation in patients with expected favorable outcomes and escalation for those with expected poor outcomes. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> rhabdomyosarcoma, pediatric, sarcoma </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Alberto Pappo (<a href="mailto:alberto.pappo@stjude.org">alberto.pappo@stjude.org</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Alberto Pappo </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> No competing interests were disclosed. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2020 Gartrell J and Pappo A. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Gartrell J and Pappo A. Recent advances in understanding and managing pediatric rhabdomyosarcoma [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):685 (<a href="https://doi.org/10.12688/f1000research.22451.1" target=_blank>https://doi.org/10.12688/f1000research.22451.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 08 Jul 2020, <b>9</b>(Faculty Rev):685 (<a href="https://doi.org/10.12688/f1000research.22451.1" target=_blank>https://doi.org/10.12688/f1000research.22451.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 08 Jul 2020, <b>9</b>(Faculty Rev):685 (<a href="https://doi.org/10.12688/f1000research.22451.1" target=_blank>https://doi.org/10.12688/f1000research.22451.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d10319e146>Introduction</h2><p class="" id=d10319e149>Rhabdomyosarcoma (RMS) is a high-grade malignant neoplasm, with a morphologic appearance mimicking that of developing skeletal muscle. It is the most common soft tissue sarcoma of childhood, accounting for 3% of all pediatric cancers<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. Currently, the overall cure rates exceed 70%, with patients who have low-, intermediate-, and high-risk disease experiencing long-term survival rates of &gt;90%, 70%, and &lt;30%, respectively<sup><a href="#ref-2">2</a>–<a href="#ref-4">4</a></sup>. Multidisciplinary care and multimodal therapies, such as chemotherapy, radiation therapy, and surgery, have led to improvements in outcomes; however, new therapies are lacking and integrative computational analyses, functional approaches, and new molecular targets will be needed to further improve the outcome of this disease. Here, we summarize the most recent advances in the biology and treatment of RMS.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d10319e169>Epidemiology</h2><p class="" id=d10319e172>RMS has an overall incidence of 4.4 cases per 1 million in individuals under the age of 20 years<sup><a href="#ref-1">1</a></sup>. Predisposing factors for the development of RMS have included germline variations (<i>DICER1</i> [urogenital and cervical embryonal RMS (eRMS)]<sup><a href="#ref-5">5</a>–<a href="#ref-7">7</a></sup>, Li-Fraumeni syndrome, Beckwith-Wiedemann syndrome, and RASopathies)<sup><a href="#ref-8">8</a></sup>, environmental factors such as prenatal X-ray exposure and maternal drug use, male sex, and age<sup><a href="#ref-1">1</a>,<a href="#ref-3">3</a>,<a href="#ref-9">9</a></sup>.</p><p class="" id=d10319e203>In a population-based study, Lupo <i>et al.</i><sup><a href="#ref-10">10</a></sup> identified familial and perinatal risk factors associated with developing soft tissue sarcomas. In an analysis of over 4 million individuals from Sweden, preterm birth was associated with an increased risk of RMS, implicating developmental pathways in the pathogenesis of the disease<sup><a href="#ref-10">10</a></sup>. In another study, Williams <i>et al.</i><sup><a href="#ref-11">11</a></sup> conducted a case-controlled study of 12,632 cases of childhood cancer from population-based cancer registries in Minnesota, New York, and Washington to determine the role of male sex on RMS oncogenesis. Male sex was directly associated with RMS, suggesting that sex-specific factors in gene expression patterns are responsible for the differences in the risk of developing childhood cancers.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d10319e225>Pathology</h2><p class="" id=d10319e228>The World Health Organization Classification of Soft Tissue and Bone identifies four prognostically different subtypes of RMS: eRMS, alveolar RMS (aRMS), pleomorphic, and spindle cell/sclerosing<sup><a href="#ref-12">12</a>–<a href="#ref-14">14</a></sup>. The two most common subtypes are eRMS and aRMS, in which eRMS accounts for 38.8% of cases and aRMS accounts for 22.3% of cases<sup><a href="#ref-1">1</a></sup>. The Children’s Oncology Group (COG) reviewed 2,192 patients enrolled in nine consecutive clinical trials to determine whether this classification system is valid for pediatric patients. They found that the system was generally valid for pediatric cohorts. Exceptions included low-risk botryoid tumors, which had an excellent prognosis, and spindle cell parameningeal tumors, which had a poor prognosis. The spindle cell/sclerosing group otherwise had a similar prognosis to eRMS, in contrast with adult data, which show that this histologic group conferred a poor prognosis. This study did not include molecular classification in the analyses, which may explain the differences between pediatric and adult data<sup><a href="#ref-15">15</a></sup>.</p><p class="" id=d10319e246>The aRMS subtype is characterized by PAX3–FOXO1 and PAX7–FOXO1 protein fusions. The COG retrospectively analyzed 1,727 patients treated in six of their most recent clinical trials. Their report found that fusion status was the most important prognostic factor for patients with localized and metastatic disease. The 5-year event free survival (EFS) rate was 52% for fusion-positive, localized disease; 6% for fusion-positive, metastatic disease; 78% for fusion-negative, localized disease; and 46% for fusion-negative metastatic disease<sup><a href="#ref-16">16</a>,<a href="#ref-17">17</a></sup>. The higher 5-year EFS rates for fusion-negative aRMS suggest that this group may unnecessarily receive therapies for high-risk disease, as these outcomes are similar to those of eRMS cases treated with intermediate-risk therapies. Therefore, this represents a group of patients in whom therapy de-escalation should occur<sup><a href="#ref-13">13</a>,<a href="#ref-16">16</a>,<a href="#ref-18">18</a>,<a href="#ref-19">19</a></sup>.</p><p class="" id=d10319e269>New molecular subtypes of RMS include <i>MYOD1</i>-mutant RMS, <i>VGLL2/NCOA2</i>-rearranged RMS, and <i>TFCP2</i>-rearranged RMS. Identification of these subtypes has clinical relevance and may allow further stratification of patients in future clinical trials. For example, patients with the spindle cell subtype who are younger than 5 years of age frequently harbor either a <i>VGLL2</i> or a <i>NCOA2</i> fusion. These tumors arise nearly exclusively in soft tissues, and small case reports have shown that these patients have excellent clinical outcomes<sup><a href="#ref-13">13</a>,<a href="#ref-20">20</a></sup>. Butel <i>et al.</i><sup><a href="#ref-21">21</a></sup> reviewed the clinical and molecular findings of 37 infants with RMS (&lt;6 months of age). They reported 22% having the spindle cell subtype and described two separate histologic pictures. Tumors with <i>VGLL2/NCOA2</i> fusions presented with a histology that was more “fibromatous-like” versus those with a “fibrosarcoma-like” picture, which had rearrangements in <i>TPM3–NTRK1</i>, <i>SYPL1–BRAF</i>, and <i>TOP2B–RAF1</i>. Both subtypes had excellent clinical outcomes. Thus, this group may be particularly favorable for the evaluation of dose de-escalation, or modifications in local control measures may be warranted.</p><p class="" id=d10319e314>The <i>MYOD1</i> mutations in the spindle cell/sclerosing subtype are found more frequently in older patients<sup><a href="#ref-9">9</a>,<a href="#ref-13">13</a></sup>. Agaram <i>et al.</i><sup><a href="#ref-9">9</a></sup> retrospectively investigated 30 cases of <i>MYOD1</i> mutant RMS, of which 15 were pediatric cases. The clinical outcomes for these patients were poor, with a 4-year survival rate of only 18% and 15 of 22 (68%) dying of disease between 12 and 68 months after diagnosis. Approximately one-third of the cases had a concomitant <i>PIK3CA</i> mutation, potentially providing a targeted therapy for these patients. RAS pathway mutations occur in 50 to 75% of intermediate- and high-risk RMS cases<sup><a href="#ref-18">18</a>,<a href="#ref-22">22</a></sup>. Although combination therapy with CDK4/6 and MEK inhibitors is an apparent rational combination, <i>in vivo</i> studies<sup><a href="#ref-18">18</a></sup> failed to show activity, suggesting that different combination strategies should be explored.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d10319e357>Genetics</h2><p class="" id=d10319e360>Casey <i>et al.</i><sup><a href="#ref-23">23</a></sup><i></i> identified 87 patients with RMS who had undergone genomic profiling with a 468-gene onco-panel. Patients with fusion-negative RMS (n = 65) had more genomic alterations and higher tumor mutational burdens (TMBs) than patients with fusion-positive RMS did. The most common genomic abnormalities in patients with fusion-negative RMS were mutations in <i>TP53</i>, <i>NF1</i>, <i>MYOD1</i>, <i>NRAS</i>,<i></i> and <i>BCOR</i>;<i></i> deletions in <i>CDKN2</i>;<i></i> and amplifications in <i>CDK4</i>, <i>MDM2</i>,<i></i> and <i>GLI.</i> In contrast, fusion-positive tumors had “quiet” genomes, with <i>CDK4</i> amplifications as the only notable genetic alterations. This study also showed that high TMB was associated with poor clinical outcomes, regardless of fusion status, stage, or treatment, suggesting that this marker could be explored further as a way of stratifying patients in the future<sup><a href="#ref-23">23</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d10319e417>Risk stratification</h2><p class="" id=d10319e420>The current staging systems for RMS include histology, post-surgical status, tumor location, nodal involvement, tumor size, patient age, and tumor stage. The European Paediatric Soft Tissue Sarcoma Study Group (EpSSG) RMS 2005 trial defined four different risk groups: low, standard, high, and very high risk (<a href="#T1">Table 1</a>). In contrast, the COG identifies only three risk groups: low, intermediate, and high (<a href="#T2">Table 2</a>). The most notable difference in these stratification systems is how the two organizations stratify patients with aRMS. Those treated in EpSSG trials are considered high risk, and those with nodal involvement are considered very high risk<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>. In contrast, patients with non-metastatic aRMS are considered intermediate risk in the current COG stratification system. These subtle differences make comparisons of outcomes-based risk assessments problematic and highlight the need for collaborative efforts to agree upon a global definition of risk group.</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. Risk stratification and treatment based on European Paediatric Soft Tissue Sarcoma Study Group completed trials.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d10319e447 class=n-a></a><thead><a name=d10319e449 class=n-a></a><tr><a name=d10319e451 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e452 class=n-a></a>Risk</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e455 class=n-a></a>Histology</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e458 class=n-a></a>Age<br class=br>(years)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e463 class=n-a></a>Nodal<br class=br>involvement</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e468 class=n-a></a>Tumor site</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e471 class=n-a></a>Tumor<br class=br>size (cm)</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e477 class=n-a></a>IRS<br class=br>group</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e482 class=n-a></a>Treatment</th></tr></thead><tbody><a name=d10319e486 class=n-a></a><tr><a name=d10319e488 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e489 class=n-a></a>Low</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e492 class=n-a></a>eRMS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e495 class=n-a></a>&lt;10 </td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e498 class=n-a></a>N0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e501 class=n-a></a>Any</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e504 class=n-a></a>≤5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e508 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e511 class=n-a></a>VA × 22 weeks</td></tr><tr><a name=d10319e514 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d10319e515 class=n-a></a>Standard</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e518 class=n-a></a>eRMS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e521 class=n-a></a>≥10 </td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e524 class=n-a></a>N0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e527 class=n-a></a>Favorable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e530 class=n-a></a>&gt;5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e534 class=n-a></a>I</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e537 class=n-a></a>IVA × 12 weeks + VA 14 weeks<br class=br>NO RT</td></tr><tr><a name=d10319e542 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e544 class=n-a></a>eRMS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e547 class=n-a></a>Any</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e550 class=n-a></a>N0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e553 class=n-a></a>Favorable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e556 class=n-a></a>Any</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e560 class=n-a></a>II–III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e563 class=n-a></a>IVA × 9 weeks + (IVA × 4 weeks<br class=br>+ VA × 8 weeks + RT) OR (IVA<br class=br>× 12 weeks + NO RT)</td></tr><tr><a name=d10319e570 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e572 class=n-a></a>eRMS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e575 class=n-a></a>&lt;10 </td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e578 class=n-a></a>N0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e581 class=n-a></a>Unfavorable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e584 class=n-a></a>≤5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e588 class=n-a></a>II–III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e591 class=n-a></a>IVA × 27 weeks + RT</td></tr><tr><a name=d10319e594 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d10319e595 class=n-a></a>High</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e598 class=n-a></a>eRMS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e601 class=n-a></a>≥10 </td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e604 class=n-a></a>N0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e607 class=n-a></a>Unfavorable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e610 class=n-a></a>&gt;5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e614 class=n-a></a>II–III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e617 class=n-a></a>IVA × 27 weeks + (vinorelbine +<br class=br>cyclophosphamide) × 24 weeks </td></tr><tr><a name=d10319e623 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e625 class=n-a></a>eRMS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e628 class=n-a></a>&lt;10 </td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e631 class=n-a></a>N1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e634 class=n-a></a>Favorable</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e637 class=n-a></a>≤5</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e641 class=n-a></a>I–III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e644 class=n-a></a>IVA × 27 weeks + (vinorelbine +<br class=br>cyclophosphamide) × 24 weeks </td></tr><tr><a name=d10319e649 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e651 class=n-a></a>aRMS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e654 class=n-a></a>Any</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e657 class=n-a></a>N0</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e660 class=n-a></a>Any</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e663 class=n-a></a>Any</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e667 class=n-a></a>Any</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e670 class=n-a></a>IVA × 27 weeks + (vinorelbine +<br class=br>cyclophosphamide) × 24 weeks </td></tr><tr><a name=d10319e675 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e676 class=n-a></a>Very high<br class=br>risk</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e681 class=n-a></a>aRMS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e684 class=n-a></a>Any</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e687 class=n-a></a>N1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e690 class=n-a></a>Any </td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e693 class=n-a></a>Any</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e697 class=n-a></a>Any</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e700 class=n-a></a>IVADo × 12 weeks + IVA ×<br class=br>15 weeks + (vinorelbine +<br class=br>cyclophosphamide) × 24 weeks</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d10319e711 class=n-a></a><p id=d10319e713> aRMS, alveolar rhabdomyosarcoma; eRMS, embryonal rhabdomyosarcoma; IVA, ifosfamide, vincristine, and actinomycin D; IVADo, ifosfamide, vincristine, actinomycin D, and doxorubicin; IRS, Intergroup Rhabdomyosarcoma Studies; RT, radiation therapy; VA, vincristine and actinomycin D.</p></div></div></div><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. Risk stratification and treatment based on Children’s Oncology Group completed and ongoing trials.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d10319e730 class=n-a></a><thead><a name=d10319e732 class=n-a></a><tr><a name=d10319e734 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e735 class=n-a></a>Risk</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e738 class=n-a></a>Protocol</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e741 class=n-a></a>Histology</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e744 class=n-a></a>Fusion<br class=br>status</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e749 class=n-a></a>TNM<br class=br>stage</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e754 class=n-a></a>IRS group</th><th align=left colspan=1 rowspan=1 valign=top><a name=d10319e758 class=n-a></a>Treatment</th></tr></thead><tbody><a name=d10319e762 class=n-a></a><tr><a name=d10319e764 class=n-a></a><td align=left colspan=1 rowspan=3 valign=top><a name=d10319e765 class=n-a></a>Low risk</td><td align=left colspan=1 rowspan=3 valign=top><a name=d10319e768 class=n-a></a>ARST0331</td><td align=left colspan=1 rowspan=3 valign=top><a name=d10319e771 class=n-a></a>eRMS</td><td align=left colspan=1 rowspan=3 valign=top><a name=d10319e774 class=n-a></a>n/a</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e777 class=n-a></a>1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e780 class=n-a></a>I–II</td><td align=left colspan=1 rowspan=3 valign=top><a name=d10319e784 class=n-a></a>VAC × 12 weeks + VA × 12 weeks</td></tr><tr><a name=d10319e787 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e789 class=n-a></a>1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e792 class=n-a></a>III (orbital)</td></tr><tr><a name=d10319e796 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e798 class=n-a></a>2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e801 class=n-a></a>I–II</td></tr><tr><a name=d10319e805 class=n-a></a><td align=left colspan=1 rowspan=6 valign=top><a name=d10319e806 class=n-a></a>Intermediate</td><td align=left colspan=1 rowspan=6 valign=top><a name=d10319e809 class=n-a></a>ARST1431<br class=br>(ongoing)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e814 class=n-a></a>eRMS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e817 class=n-a></a>n/a</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e820 class=n-a></a>1</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e823 class=n-a></a>III (non-<br class=br>orbital)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e829 class=n-a></a>VAC/VI +/– temsirolimus × 42 weeks<br class=br> + cyclophosphamide + vinorelbine ×<br class=br>23 weeks</td></tr><tr><a name=d10319e836 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e838 class=n-a></a>eRMS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e841 class=n-a></a>n/a</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e844 class=n-a></a>3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e847 class=n-a></a>I–II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e850 class=n-a></a>VAC/VI +/– temsirolimus × 42 weeks<br class=br>+ cyclophosphamide + vinorelbine ×<br class=br>23 weeks</td></tr><tr><a name=d10319e858 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e860 class=n-a></a>eRMS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e863 class=n-a></a>n/a</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e866 class=n-a></a>2–3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e869 class=n-a></a>III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e872 class=n-a></a>VAC/VI +/– temsirolimus × 42 weeks<br class=br>+ cyclophosphamide + vinorelbine ×<br class=br>23 weeks</td></tr><tr><a name=d10319e879 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e881 class=n-a></a>eRMS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e884 class=n-a></a>n/a</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e887 class=n-a></a>4 (age<br class=br>&lt;10<br class=br>years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e894 class=n-a></a>IV (age<br class=br>&lt;10 years)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e899 class=n-a></a>VAC/VI +/– temsirolimus × 42 weeks<br class=br>+ cyclophosphamide + vinorelbine ×<br class=br>23 weeks</td></tr><tr><a name=d10319e906 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e908 class=n-a></a>aRMS </td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e911 class=n-a></a>+</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e914 class=n-a></a>1–3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e917 class=n-a></a>I–III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e920 class=n-a></a>VAC/VI +/– temsirolimus × 42 weeks<br class=br>+ cyclophosphamide + vinorelbine ×<br class=br>23 weeks</td></tr><tr><a name=d10319e927 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e929 class=n-a></a>aRMS </td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e932 class=n-a></a>–</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e935 class=n-a></a>1–2</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e938 class=n-a></a>I–II + III<br class=br>(orbit)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e943 class=n-a></a>VAC × 12 weeks + VA × 12 weeks</td></tr><tr><a name=d10319e946 class=n-a></a><td align=left colspan=1 rowspan=2 valign=top><a name=d10319e947 class=n-a></a>High risk</td><td align=left colspan=1 rowspan=2 valign=top><a name=d10319e950 class=n-a></a>ARST0431 </td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e953 class=n-a></a>eRMS</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e956 class=n-a></a>n/a</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e959 class=n-a></a>4 </td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e962 class=n-a></a>IV (age ≥10<br class=br>years)</td><td align=left colspan=1 rowspan=2 valign=top><a name=d10319e968 class=n-a></a>VDC/IfosE + VI × 54 weeks </td></tr><tr><a name=d10319e971 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e973 class=n-a></a>aRMS </td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e976 class=n-a></a>+/–</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e979 class=n-a></a>4</td><td align=left colspan=1 rowspan=1 valign=top><a name=d10319e982 class=n-a></a>IV</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d10319e990 class=n-a></a><p id=d10319e992> aRMS, alveolar rhabdomyosarcoma; eRMS, embryonal rhabdomyosarcoma; IfosE, ifosfamide and etoposide; IRS, Intergroup Rhabdomyosarcoma Studies; n/a, not applicable; TNM, tumor, node, and metastasis; VA, vincristine and actinomycin D; VAC, vincristine, actinomycin D, and cyclophosphamide; VDC, vincristine, doxorubicin, and cyclophosphamide; VI, vincristine and irinotecan.</p></div></div></div><p class="" id=d10319e998>More recently, the COG has incorporated fusion status into their risk stratification system. For example, in the current COG ARST1431 trial (NCT02567435), patients with fusion-negative stage 1, group I/II; stage 1, group III orbital; or stage 2, group I/II disease are treated with a similar strategy as that for patients with low-risk disease. Additional efforts should be made to incorporate novel subtypes, such as those with <i>MYOD1</i> mutations, increased TMB, VGLL2 and NCOA2 protein fusions, or <i>TP53</i> mutations, into risk-stratification systems for clinical trials<sup><a href="#ref-9">9</a>,<a href="#ref-13">13</a>,<a href="#ref-20">20</a></sup>.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d10319e1021>Advances in the treatment of RMS</h2><p class="" id=d10319e1024>Using the COG’s current risk group classification (<a href="#T2">Table 2</a>), we describe the most recent treatment advances in these subsets.</p><div class=section><a name=d10319e1030 class=n-a></a><h3 class=section-title>Low-risk disease</h3><p class="" id=d10319e1035>Patients with low-risk RMS have survival rates exceeding 90%; therefore, this population is appropriate for studies with less-intense therapies to limit acute and long-term toxicities<sup><a href="#ref-26">26</a></sup>. The COG ARST0331 (NCT00075582) trial was designed to decrease exposure to alkylating agents and reduce the duration of therapy in selected groups of patients with low-risk disease. Patients with stage 1–2, group I–II or with stage 1, group III orbital eRMS tumors were treated with 22 weeks of therapy. The treatment regimen comprised four cycles of vincristine, actinomycin D, and cyclophosphamide (VAC), with a total cyclophosphamide cumulative dose of 4.8 g/m<sup>2</sup>, followed by four cycles of vincristine and actinomycin D. In addition, radiation doses were decreased from 41.4 Gy to 36 Gy for patients with group IIA and from 50.4 Gy to 45 Gy for those with orbital group III eRMS tumors. Over a 6-year period, 271 patients were enrolled in the trial. The most common primary tumor sites were paratesticular (n = 118) and orbital (n = 82). The 3-year failure-free survival (FFS) and overall survival (OS) rates were 89% and 98%, respectively. For specific sites, the 3-year FFS and OS rates were 93% and 99% for paratesticular tumors, 86% and 97% for orbital tumors, and 86% and 97% for all other patients, respectively<sup><a href="#ref-26">26</a></sup>. Patients with orbital tumors who were treated with 45 Gy of radiation and did not achieve a complete response after 12 weeks of chemotherapy had higher local failure rates, but the OS rate was similar between the two groups<sup><a href="#ref-27">27</a></sup>. In contrast to these excellent results, patients with embryonal stage 1 group III non-orbital tumors or stage 3 group I/II were treated with four VAC cycles and 12 cycles of vincristine and actinomycin D (VA) and experienced a lower FFS of 70% and OS of 92%, mainly owing to local failures in patients with genital tract tumors<sup><a href="#ref-28">28</a></sup>. Therefore, this group of patients are now considered intermediate risk.</p><p class="" id=d10319e1057>The EpSSG is evaluating therapy for patients with low-risk RMS by eliminating cyclophosphamide from therapy for patients who are younger than 10 years old and have a group I eRMS tumor that is &lt;5 cm with no nodal involvement. The results of this trial will inform future therapies for pediatric patients with low-risk RMS.</p></div><div class=section><a name=d10319e1061 class=n-a></a><h3 class=section-title>Intermediate-risk disease</h3><p class="" id=d10319e1066>Over 50% of patients with RMS have intermediate-risk disease. These patients have either nonmetastatic eRMS with an unfavorable primary site or nonmetastatic aRMS. The OS rate for this group approaches 75%<sup><a href="#ref-4">4</a></sup>, with no marked improvements occurring in the last few decades. The COG developed a randomized study (ARST0531; NCT00354835) to improve outcomes in this group by incorporating vincristine and irinotecan (VI) into the VAC backbone. The rationale for incorporating VI was based on the very high rates of response (70%) occurring in patients with high-risk RMS who were treated with two courses of VI as a window therapy<sup><a href="#ref-29">29</a>,<a href="#ref-30">30</a></sup>. The ARST0531 trial randomized 448 patients to receive either VAC or VAC/VI, in which VI replaced VAC in weeks 16, 19, 25, 31, and 37<sup><a href="#ref-30">30</a></sup>. The trial design resulted in a 45% dose reduction of cyclophosphamide in the VAC group and a 66% reduction of cyclophosphamide in the VAC/VI group as compared with a previous intermediate-risk group trial (D9803; NCT00003958)<sup><a href="#ref-31">31</a></sup>. The two arms had similar outcomes, with a 4-year EFS rate of 63% in the VAC group and 59% in the VAC/VI group (<i>P</i> = 0.51). Despite a lack of improvement between the two groups, the VAC/VI group had lower rates of anemia, thrombocytopenia, and febrile neutropenia but higher rates of diarrhea and mucositis<sup><a href="#ref-30">30</a></sup>.</p><p class="" id=d10319e1096>Further analysis of this trial demonstrated that the rates of local failure were higher than those of the D9803 trial. The local failure rates for patients with tumors &gt;5 cm were 32.3% versus 16.7% (<i>P</i> = 0.001) and 27.9% versus 19.4% for those with group III eRMS (<i>P</i> = 0.03)<sup><a href="#ref-32">32</a></sup>. In addition, the EFS and OS rates for patients in the ARST0531 trial were lower than those for patients in the D9803 trial. These differences were most apparent for patients with stage 2/3, group III eRMS tumors, comprising 54% of the patients enrolled in the ARST0531 trial. The reasons for this difference are not entirely clear but may be related to lower cumulative doses of cyclophosphamide<sup><a href="#ref-31">31</a>,<a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup>. Increased failure rates have been observed in patients with head and neck RMS treated with lower doses of cyclophosphamide<sup><a href="#ref-31">31</a>,<a href="#ref-33">33</a>,<a href="#ref-34">34</a></sup>, and improvements in outcomes were found in the EpSSG RMS 2005 study for patients treated with higher doses of cyclophosphamide<sup><a href="#ref-24">24</a>,<a href="#ref-31">31</a></sup>. This supports the notion that there may be a minimal dose threshold of alkylating agent required with current treatment strategies.</p><p class="" id=d10319e1137>The EpSSG RMS 2005 trial randomized patients with high-risk RMS (patients with nonmetastatic, incompletely resected RMS, eRMS occurring at unfavorable sites, age 10 years or older or with a tumor size of &gt;5 cm or both, and any nonmetastatic eRMS with nodal involvement), who were stratified in a similar way to that of intermediate-risk RMS in the COG trial (<a href="#T2">Table 2</a>), into two consecutive independent randomized trials. In the first trial, 484 patients were randomized to receive nine cycles of ifosfamide, vincristine, and actinomycin D (IVA) or four cycles of IVA and doxorubicin (IVADo) followed by five cycles of IVA. Patients who were in remission following upfront therapy were randomized on the second trial to either stop treatment or receive a maintenance regimen with low-dose cyclophosphamide and vinorelbine. The addition of doxorubicin only increased toxicity without improving survival, with a 3-year EFS of 67.5% in the IVADo group and 63.3% in the IVA group<sup><a href="#ref-25">25</a></sup>. However, the addition of maintenance therapy in the second trial improved disease-free survival (77.6% with maintenance versus 69.8% without) and OS (86.5% with maintenance versus 73.7% without)<sup><a href="#ref-24">24</a></sup>. Of the initial 670 patients assessed for eligibility for the maintenance trial, 12.1% were excluded because they did not achieve remission at the end of standard of treatment<sup><a href="#ref-24">24</a></sup>. Additional follow-up is needed to determine the impact of maintenance therapy on long-term survival.</p><p class="" id=d10319e1155>On the basis of the improvements found in the EpSSG RMS 2005 maintenance trial, the COG’s current trial for intermediate-risk disease (ARST1431; NCT02567435) will use the same VAC/VI backbone used in ARST0531 but adopt the maintenance approach with vinorelbine and cyclophosphamide, increasing the total cumulative cyclophosphamide dose from 8.4 g/m<sup>2</sup> to 12.6 g/m<sup>2</sup>. The importance of duration versus total cumulative dose of cyclophosphamide is not yet known.</p></div><div class=section><a name=d10319e1165 class=n-a></a><h3 class=section-title>High-risk disease</h3><p class="" id=d10319e1170>Historically, the outcomes for patients with metastatic RMS are poor, with &lt;30% surviving long term. The COG ARST0431 trial enrolled 109 patients with metastatic disease to receive 54 weeks of therapy, consisting of VI (weeks 1–6, 20–25, and 47–52) with interval compressed vincristine/doxorubicin/cyclophosphamide alternating with etoposide/ifosfamide (weeks 7–19 and 26–34) and then VAC (weeks 38–46). They found that the number of Oberlin risk factors—age &gt;10 years or &lt;1 year, unfavorable primary site of disease, three or more metastatic sites, and bone or bone marrow involvement—had prognostic significance. The patients with no or one Oberlin risk factor (n = 43) had improved outcomes over those of historical control cohorts. The EFS was 67% in the ARST0431 trial and 44% in the Oberlin-controlled cohort; however, those with two or more risk factors experienced poor outcomes, with an EFS of 19% in the ARST0431 trial and 14% in the Oberlin-controlled cohort. Furthermore, when the patients were stratified by histology, only those with eRMS experienced benefits from this treatment regimen<sup><a href="#ref-35">35</a></sup>.</p><p class="" id=d10319e1177>Another recently completed COG non-randomized trial (ARST08P1; NCT01055314) explored the addition of either an insulin-like growth factor-1 receptor monoclonal antibody, cixutumumab, or temozolomide to the ARST0431 trial backbone. There were 168 patients enrolled, 70% of whom had aRMS. Patients who were &lt;10 years old with eRMS were initially excluded until safety was determined. With a median follow-up of 2.9 years, the 3-year EFS was 16% (95% confidence interval [CI]: 7–25%) with cixutumumab and 18% (95% CI: 2–35%) with temozolomide. Both arms had an inferior EFS compared to the EFS of 38% achieved in ARST0431. This may be due in part to the early exclusion of the young eRMS cohort. Consistent with ARST0431, Oberlin risk factors continued to be prognostic, with patients with fewer than two Oberlin risk factors having a 3-year EFS of 38% compared to an EFS of 9% for those with two or more Oberlin risk factors. For both Oberlin risk groups, the EFS was inferior to those patients treated on ARST0431<sup><a href="#ref-36">36</a></sup>.</p><p class="" id=d10319e1184>The EpSSG BERNIE study randomized 103 patients with metastatic RMS and 49 patients with metastatic non-RMS soft tissue sarcoma to receive either IVADo alone or in combination with the VEGF inhibitor bevacizumab, followed by maintenance chemotherapy with cyclophosphamide and vinorelbine with or without bevacizumab. The hazard rate for EFS in patients with RMS was 1.24 (95% CI: 0.73–2.09). The independent review committee (IRC) response rate for aRMS was 64% with bevacizumab (95% CI: 42.5–82) and 53.1% (95% CI: 34.7–70.9) without bevacizumab. For eRMS, the IRC response rate was 66.7% with bevacizumab (95% CI: 41–86.7) and 53.3% (95% CI: 26.6–78.7) without bevacizumab. The 2-year EFS remained 41% for both treatment groups<sup><a href="#ref-37">37</a></sup>. Therefore, it is clear that new treatment strategies are needed for patients with metastatic RMS.</p></div><div class=section><a name=d10319e1193 class=n-a></a><h3 class=section-title>Recurrent/refractory disease</h3><p class="" id=d10319e1198>Most patients with recurrent/refractory disease experience poor clinical outcomes. To determine whether delayed diagnosis contributes to such poor outcomes in some patients, the EpSSG conducted a retrospective study comparing 78 patients who had imaging performed routinely to 121 patients who had imaging performed on the basis of symptoms alone. The patients who received routine imaging had their disease detected earlier than those who did not (8 versus 12 months); however, this did not improve survival, suggesting that the poor outcomes cannot be explained solely by delayed diagnosis<sup><a href="#ref-38">38</a></sup>.</p><p class="" id=d10319e1205>The Italian Soft Tissue Sarcoma Committee treated 38 patients with progressive or recurrent disease with two cycles of topotecan and carboplatin, followed by four cycles of topotecan and cyclophosphamide and alternating with carboplatin and etoposide. Of 38 patients, 32 completed the therapy with an overall response rate of 37.5% (35% for aRMS versus 20% for eRMS). Nevertheless, this did not improve OS, which remained at 17%<sup><a href="#ref-39">39</a></sup>.</p><p class="" id=d10319e1212>The COG study ARST0121 enrolled 139 patients experiencing first recurrence/relapse and divided them into four treatment groups based on risk groups. Those with “unfavorable risk factors” (initial stage 2–4, clinical group II–IV eRMS, initial stage I or clinical group I eRMS with distant recurrence after VA or recurrence after VAC, and aRMS) were randomized to receive differing schedules of window therapy with VI followed by dose-intensive chemotherapy with vincristine/doxorubicin/cyclophosphamide/ifosfamide/etoposide/irinotecan. If they refused window therapy, or had prior irinotecan exposure, window therapy and irinotecan were omitted and a new agent, tirapazamine (TPZ), was added. Alternatively, those with “favorable risk” disease (botryoid histology, or stage 1, or locally or regionally recurring clinical group I eRMS at initial diagnosis not treated with cyclophosphamide) received the chemotherapy regimen without window therapy, irinotecan, or TPZ. While patients with unfavorable risk continued to have poor outcomes (FFS 14% and 15% with window therapy regimens, 21% with TPZ), the study confirmed that those with favorable risk had good outcomes (FFS 79%, OS 84%)<sup><a href="#ref-40">40</a></sup>.</p><p class="" id=d10319e1219>The COG study ARST0921 (NCT01222715) randomized 87 patients with a first recurrence to receive either bevacizumab or temsirolimus in combination with vinorelbine and cyclophosphamide. The patients who received temsirolimus had a superior EFS than did those who received bevacizumab. The 6-month EFS was 69.1% for patients who received temsirolimus and 54.6% for those who received bevacizumab; however, the 24-month EFS was less than 20% for both groups, with 19.1% for temsirolimus and 6.8% for bevacizumab<sup><a href="#ref-41">41</a></sup>.</p><p class="" id=d10319e1227>To identify new targeted therapies, Stewart <i>et al.</i> used orthotopic patient-derived xenograft models to perform an integrated transcriptomic, epigenetic, and proteomic/phosphoproteomic analysis of refractory RMS tumors and identified significant activity with the WEE1 inhibitor AZD1775 in combination with vincristine and irinotecan (NCT02095132)<sup><a href="#ref-42">42</a></sup>.</p><p class="" id=d10319e1237>Yan <i>et al.</i><sup><a href="#ref-43">43</a></sup> used immunodeficient zebrafish to successfully engraft both eRMS and aRMS patient-derived xenografts, offering an opportunity to expand preclinical testing in this disease. They identified that the combination of olaparib with temozolomide was active and validated these findings in cell lines and patient-derived xenograft mouse models.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d10319e1250>Conclusion</h2><p class="" id=d10319e1253>Despite advances in the cellular and genomic classification of RMS and the introduction of combined modality therapy, outcomes for patients at high risk for treatment failure remain suboptimal. In addition, patients who survive their disease are at high risk of developing long-term sequelae as a result of systemic and local therapies. Additional progress will require the development of accurate models that recapitulate human disease, integration of genomics in risk classification, biomarker development, and better informatics that allow for the creation of a data commons to seamlessly integrate data to catalyze discovery.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d10319e1 class=n-a></a><h2 class=main-title id=d10483>Author contributions</h2><p class=metadata-entry><a name=d10319e89 class=n-a></a><p id=d10319e90> Both authors contributed to the conceptualization, original draft preparation, and review and editing of this work.</p></p></div><div class=back-section><a name=d10319e1260 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class=faculty-opinion-icon></span><span class="prime-red big">Faculty Opinions recommended</span></span><h2 class=main-title id=d10636>References</h2><div class="section ref-list"><a name=d10319e1260 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735908469"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1267 class=n-a></a>Amer KM, Thomson JE, Congiusta D, <i> et al.</i>: Epidemiology, Incidence, and Survival of Rhabdomyosarcoma Subtypes: SEER and ICES Database Analysis. <i>J Orthop Res.</i> 2019; <b>37</b>(10): 2226–2230. <a target=xrefwindow id=d10319e1278 href="http://www.ncbi.nlm.nih.gov/pubmed/31161653">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1281 href="https://doi.org/10.1002/jor.24387">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735908469">Faculty Opinions Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736028885"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1294 class=n-a></a>Yohe ME, Heske CM, Stewart E, <i> et al.</i>: Insights into pediatric rhabdomyosarcoma research: Challenges and goals. <i>Pediatr Blood Cancer.</i> 2019; <b>66</b>(10): e27869. <a target=xrefwindow id=d10319e1305 href="http://www.ncbi.nlm.nih.gov/pubmed/31222885">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1308 href="https://doi.org/10.1002/pbc.27869">Publisher Full Text </a> | <a target=xrefwindow id=d10319e1312 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6707829">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736028885">Faculty Opinions Recommendation</a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734822129"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1325 class=n-a></a>Rhabdomyosarcoma. <i>Nat Rev Dis Primers.</i> 2019; <b>5</b>(1): 2. <a target=xrefwindow id=d10319e1333 href="http://www.ncbi.nlm.nih.gov/pubmed/30617267">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1336 href="https://doi.org/ 10.1038/s41572-018-0057-9">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734822129">Faculty Opinions Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d10319e1349 class=n-a></a>Goldblum JF, Folpe AL, Weiss SW: Enzinger and Weiss's Soft Tissue Tumors. 6 ed. Philadelphia, PA: Elsevier Saunders; 2014. <a target=xrefwindow id=d10319e1351 href="https://www.elsevier.com/books/enzinger-and-weisss-soft-tissue-tumors/goldblum/978-0-323-08834-3">Reference Source</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a name=d10319e1360 class=n-a></a>Schultz KAP, Williams GM, Kamihara J, <i> et al.</i>: <i>DICER1</i> and Associated Conditions: Identification of At-risk Individuals and Recommended Surveillance Strategies. <i>Clin Cancer Res.</i> 2018; <b>24</b>(10): 2251–2261. <a target=xrefwindow id=d10319e1374 href="http://www.ncbi.nlm.nih.gov/pubmed/29343557">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1378 href="https://doi.org/10.1158/1078-0432.CCR-17-3089">Publisher Full Text </a> | <a target=xrefwindow id=d10319e1381 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6260592">Free Full Text </a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737285476"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1391 class=n-a></a>McCluggage WG, Apellaniz-Ruiz M, Chong AL, <i> et al.</i>: Embryonal Rhabdomyosarcoma of the Ovary and Fallopian Tube: Rare Neoplasms Associated With Germline and Somatic DICER1 Mutations. <i>Am J Surg Pathol.</i> 2020; <b>44</b>(6): 738–747. <a target=xrefwindow id=d10319e1402 href="http://www.ncbi.nlm.nih.gov/pubmed/31990691">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1405 href="https://doi.org/10.1097/PAS.0000000000001442">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737285476">Faculty Opinions Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d10319e1418 class=n-a></a>Warren M, Hiemenz MC, Schmidt R, <i> et al.</i>: Expanding the spectrum of dicer1-associated sarcomas. <i>Mod Pathol.</i> 2020; <b>33</b>(1): 164–174. <a target=xrefwindow id=d10319e1429 href="http://www.ncbi.nlm.nih.gov/pubmed/31537896">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1432 href="https://doi.org/10.1038/s41379-019-0366-x">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d10319e1441 class=n-a></a>Salem B, Hofherr S, Turner J, <i> et al.</i>: Childhood Rhabdomyosarcoma in Association With a RASopathy Clinical Phenotype and Mosaic Germline SOS1 Duplication. <i>J Pediatr Hematol Oncol.</i> 2016; <b>38</b>(8): e278–e282. <a target=xrefwindow id=d10319e1452 href="http://www.ncbi.nlm.nih.gov/pubmed/27258033">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1455 href="https://doi.org/10.1097/MPH.0000000000000566">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733952255"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1464 class=n-a></a>Agaram NP, LaQuaglia MP, Alaggio R, <i> et al.</i>: <i>MYOD1</i>-mutant spindle cell and sclerosing rhabdomyosarcoma: An aggressive subtype irrespective of age. A reappraisal for molecular classification and risk stratification. <i>Mod Pathol.</i> 2019; <b>32</b>(1): 27–36. <a target=xrefwindow id=d10319e1478 href="http://www.ncbi.nlm.nih.gov/pubmed/30181563">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1482 href="https://doi.org/10.1038/s41379-018-0120-9">Publisher Full Text </a> | <a target=xrefwindow id=d10319e1485 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6720105">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733952255">Faculty Opinions Recommendation</a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735543879"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1498 class=n-a></a>Lupo PJ, Luna-Gierke RE, Chambers TM, <i> et al.</i>: Perinatal and familial risk factors for soft tissue sarcomas in childhood through young adulthood: A population-based assessment in 4 million live births. <i>Int J Cancer.</i> 2020; <b>146</b>(3): 791–802. <a target=xrefwindow id=d10319e1509 href="http://www.ncbi.nlm.nih.gov/pubmed/30980537">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1512 href="https://doi.org/10.1002/ijc.32335">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735543879">Faculty Opinions Recommendation</a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734097566"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1525 class=n-a></a>Williams LA, Richardson M, Kehm RD, <i> et al.</i>: The association between sex and most childhood cancers is not mediated by birthweight. <i>Cancer Epidemiol.</i> 2018; <b>57</b>: 7–12. <a target=xrefwindow id=d10319e1536 href="http://www.ncbi.nlm.nih.gov/pubmed/30248472">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1539 href="https://doi.org/10.1016/j.canep.2018.09.002">Publisher Full Text </a> | <a target=xrefwindow id=d10319e1543 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6289597">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734097566">Faculty Opinions Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d10319e1557 class=n-a></a>Jo VY, Fletcher CDM: WHO classification of soft tissue tumours: An update based on the 2013 (4th) edition. <i>Pathology.</i> 2014; <b>46</b>(2): 95–104. <a target=xrefwindow id=d10319e1565 href="http://www.ncbi.nlm.nih.gov/pubmed/24378391">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1568 href="https://doi.org/10.1097/PAT.0000000000000050">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736941331"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1577 class=n-a></a>Leiner J, Le Loarer F: The current landscape of rhabdomyosarcomas: An update. <i>Virchows Arch.</i> 2020; <b>476</b>(1): 97–108. <a target=xrefwindow id=d10319e1585 href="http://www.ncbi.nlm.nih.gov/pubmed/31696361">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1588 href="https://doi.org/10.1007/s00428-019-02676-9">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736941331">Faculty Opinions Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d10319e1601 class=n-a></a>Pappo AS, Dirksen U: Rhabdomyosarcoma, Ewing Sarcoma, and Other Round Cell Sarcomas. <i>J Clin Oncol.</i> 2018; <b>36</b>(2): 168–79. <a target=xrefwindow id=d10319e1609 href="http://www.ncbi.nlm.nih.gov/pubmed/29220292">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1612 href="https://doi.org/10.1200/JCO.2017.74.7402">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d10319e1621 class=n-a></a>Rudzinski ER, Anderson JR, Hawkins DS, <i> et al.</i>: The World Health Organization Classification of Skeletal Muscle Tumors in Pediatric Rhabdomyosarcoma: A Report From the Children's Oncology Group. <i>Arch Pathol Lab Med.</i> 2015; <b>139</b>(10): 1281–7. <a target=xrefwindow id=d10319e1632 href="http://www.ncbi.nlm.nih.gov/pubmed/25989287">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1635 href="https://doi.org/10.5858/arpa.2014-0475-OA">Publisher Full Text </a> | <a target=xrefwindow id=d10319e1639 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4651658">Free Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736510186"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1648 class=n-a></a>Hibbitts E, Chi YY, Hawkins DS, <i> et al.</i>: Refinement of risk stratification for childhood rhabdomyosarcoma using FOXO1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group. <i>Cancer Med.</i> 2019; <b>8</b>(14): 6437–48. <a target=xrefwindow id=d10319e1659 href="http://www.ncbi.nlm.nih.gov/pubmed/31456361">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1662 href="https://doi.org/10.1002/cam4.2504">Publisher Full Text </a> | <a target=xrefwindow id=d10319e1666 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6797586">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736510186">Faculty Opinions Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718113512"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1679 class=n-a></a>Skapek SX, Anderson J, Barr FG, <i> et al.</i>: <i>PAX-FOXO1</i> fusion status drives unfavorable outcome for children with rhabdomyosarcoma: A children's oncology group report. <i>Pediatr Blood Cancer.</i> 2013; <b>60</b>(9): 1411–7. <a target=xrefwindow id=d10319e1693 href="http://www.ncbi.nlm.nih.gov/pubmed/23526739">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1697 href="https://doi.org/10.1002/pbc.24532">Publisher Full Text </a> | <a target=xrefwindow id=d10319e1700 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4646073">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718113512">Faculty Opinions Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d10319e1714 class=n-a></a>Stewart E, McEvoy J, Wang H, <i> et al.</i>: Identification of Therapeutic Targets in Rhabdomyosarcoma through Integrated Genomic, Epigenomic, and Proteomic Analyses. <i>Cancer Cell.</i> 2018; <b>34</b>(3): 411–426.e19. <a target=xrefwindow id=d10319e1725 href="http://www.ncbi.nlm.nih.gov/pubmed/30146332">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1728 href="https://doi.org/10.1016/j.ccell.2018.07.012">Publisher Full Text </a> | <a target=xrefwindow id=d10319e1732 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6158019">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d10319e1741 class=n-a></a>Arnold MA, Barr FG: Molecular diagnostics in the management of rhabdomyosarcoma. <i>Expert Rev Mol Diagn.</i> 2017; <b>17</b>(2): 189–94. <a target=xrefwindow id=d10319e1749 href="http://www.ncbi.nlm.nih.gov/pubmed/28058850">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1752 href="https://doi.org/10.1080/14737159.2017.1275965">Publisher Full Text </a> | <a target=xrefwindow id=d10319e1755 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5657295">Free Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/725925781"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1764 class=n-a></a>Alaggio R, Zhang L, Sung YS, <i> et al.</i>: A Molecular Study of Pediatric Spindle and Sclerosing Rhabdomyosarcoma: Identification of Novel and Recurrent VGLL2-related Fusions in Infantile Cases. <i>Am J Surg Pathol.</i> 2016; <b>40</b>(2): 224–35<a target=xrefwindow id=d10319e1775 href="http://www.ncbi.nlm.nih.gov/pubmed/26501226">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1778 href="https://doi.org/10.1097/PAS.0000000000000538">Publisher Full Text </a> | <a target=xrefwindow id=d10319e1782 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4712098">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/725925781">Faculty Opinions Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737418211"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1795 class=n-a></a>Butel T, Karanian M, Pierron G, <i> et al.</i>: Integrative clinical and biopathology analyses to understand the clinical heterogeneity of infantile rhabdomyosarcoma: A report from the French MMT committee. <i>Cancer Med.</i> 2020; <b>9</b>(8): 2698–2709. <a target=xrefwindow id=d10319e1806 href="https://doi.org/10.1002/cam4.2713">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737418211">Faculty Opinions Recommendation</a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718206957"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1819 class=n-a></a>Chen X, Stewart E, Shelat AA, <i> et al.</i>: Targeting Oxidative Stress in Embryonal Rhabdomyosarcoma. <i>Cancer Cell.</i> 2013; <b>24</b>(6): 710–24. <a target=xrefwindow id=d10319e1830 href="http://www.ncbi.nlm.nih.gov/pubmed/24332040">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1833 href="https://doi.org/10.1016/j.ccr.2013.11.002">Publisher Full Text </a> | <a target=xrefwindow id=d10319e1837 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3904731">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718206957">Faculty Opinions Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736877533"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1850 class=n-a></a>Casey DL, Wexler LH, Pitter KL, <i> et al.</i>: Genomic Determinants of Clinical Outcomes in Rhabdomyosarcoma. <i>Clin Cancer Res.</i> 2020; <b>26</b>: 1135–40. <a target=xrefwindow id=d10319e1861 href="https://doi.org/10.1158/1078-0432.CCR-19-2631">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736877533">Faculty Opinions Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736678741"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1875 class=n-a></a>Bisogno G, de Salvo GL, Bergeron C, <i> et al.</i>: Vinorelbine and continuous low-dose cyclophosphamide as maintenance chemotherapy in patients with high-risk rhabdomyosarcoma (RMS 2005): A multicentre, open-label, randomised, phase 3 trial. <i>Lancet Oncol.</i> 2019; <b>20</b>(11): 1566–1575. <a target=xrefwindow id=d10319e1886 href="http://www.ncbi.nlm.nih.gov/pubmed/31562043">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1889 href="https://doi.org/10.1016/S1470-2045(19)30617-5">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736678741">Faculty Opinions Recommendation</a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733512630"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1902 class=n-a></a>Bisogno G, Jenney M, Bergeron C, <i> et al.</i>: Addition of dose-intensified doxorubicin to standard chemotherapy for rhabdomyosarcoma (EpSSG RMS 2005): A multicentre, open-label, randomised controlled, phase 3 trial. <i>Lancet Oncol.</i> 2018; <b>19</b>(8): 1061–1071. <a target=xrefwindow id=d10319e1913 href="http://www.ncbi.nlm.nih.gov/pubmed/29941280">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1916 href="https://doi.org/10.1016/S1470-2045(18)30337-1">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733512630">Faculty Opinions Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/718893971"><span class="faculty-opinion-icon small"></span></a><a name=d10319e1929 class=n-a></a>Walterhouse DO, Pappo AS, Meza JL, <i> et al.</i>: Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. <i>J Clin Oncol.</i> 2014; <b>32</b>(31): 3547–52. <a target=xrefwindow id=d10319e1940 href="http://www.ncbi.nlm.nih.gov/pubmed/25267746">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1943 href="https://doi.org/10.1200/JCO.2014.55.6787">Publisher Full Text </a> | <a target=xrefwindow id=d10319e1947 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4209105">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/718893971">Faculty Opinions Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d10319e1960 class=n-a></a>Ermoian RP, Breneman J, Walterhouse DO, <i> et al.</i>: 45 Gy is not sufficient radiotherapy dose for Group III orbital embryonal rhabdomyosarcoma after less than complete response to 12 weeks of ARST0331 chemotherapy: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. <i>Pediatr Blood Cancer.</i> 2017; <b>64</b>(9): e26540. <a target=xrefwindow id=d10319e1971 href="http://www.ncbi.nlm.nih.gov/pubmed/28548706">PubMed Abstract </a> | <a target=xrefwindow id=d10319e1974 href="https://doi.org/10.1002/pbc.26540">Publisher Full Text </a> | <a target=xrefwindow id=d10319e1978 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5568701">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d10319e1987 class=n-a></a>Walterhouse DO, Pappo AS, Meza JL, <i> et al.</i>: Reduction of cyclophosphamide dose for patients with subset 2 low-risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. <i>Cancer.</i> 2017; <b>123</b>(12): 2368–2375. <a target=xrefwindow id=d10319e1998 href="http://www.ncbi.nlm.nih.gov/pubmed/28211936">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2001 href="https://doi.org/10.1002/cncr.30613">Publisher Full Text </a> | <a target=xrefwindow id=d10319e2005 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5662934">Free Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d10319e2014 class=n-a></a>Pappo AS, Lyden E, Breitfeld P, <i> et al.</i>: Two consecutive phase II window trials of irinotecan alone or in combination with vincristine for the treatment of metastatic rhabdomyosarcoma: The Children's Oncology Group. <i>J Clin Oncol.</i> 2007; <b>25</b>(4): 362–9. <a target=xrefwindow id=d10319e2025 href="http://www.ncbi.nlm.nih.gov/pubmed/17264331">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2028 href="https://doi.org/10.1200/JCO.2006.07.1720">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/733793322"><span class="faculty-opinion-icon small"></span></a><a name=d10319e2038 class=n-a></a>Hawkins DS, Chi YY, Anderson JR, <i> et al.</i>: Addition of Vincristine and Irinotecan to Vincristine, Dactinomycin, and Cyclophosphamide Does Not Improve Outcome for Intermediate-Risk Rhabdomyosarcoma: A Report From the Children’s Oncology Group. <i>J Clin Oncol.</i> 2018; <b>36</b>(27): 2770–2777. <a target=xrefwindow id=d10319e2049 href="http://www.ncbi.nlm.nih.gov/pubmed/30091945">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2052 href="https://doi.org/10.1200/JCO.2018.77.9694">Publisher Full Text </a> | <a target=xrefwindow id=d10319e2056 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6145831">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/733793322">Faculty Opinions Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d10319e2069 class=n-a></a>Lucas JT, Pappo AS: Optimal dosing of cyclophosphamide in rhabdomyosarcoma: It's complicated. <i>Cancer.</i> 2019; <b>125</b>(18): 3107–10. <a target=xrefwindow id=d10319e2077 href="http://www.ncbi.nlm.nih.gov/pubmed/31174230">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2080 href="https://doi.org/10.1002/cncr.32205">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735923658"><span class="faculty-opinion-icon small"></span></a><a name=d10319e2089 class=n-a></a>Casey DL, Chi YY, Donaldson SS, <i> et al.</i>: Increased local failure for patients with intermediate-risk rhabdomyosarcoma on ARST0531: A report from the Children's Oncology Group. <i>Cancer.</i> 2019; <b>125</b>(18): 3242–8. <a target=xrefwindow id=d10319e2100 href="http://www.ncbi.nlm.nih.gov/pubmed/31174239">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2103 href="https://doi.org/10.1002/cncr.32204">Publisher Full Text </a> | <a target=xrefwindow id=d10319e2107 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6717036">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735923658">Faculty Opinions Recommendation</a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734599168"><span class="faculty-opinion-icon small"></span></a><a name=d10319e2120 class=n-a></a>Casey DL, Wexler LH, Wolden SL: Worse Outcomes for Head and Neck Rhabdomyosarcoma Secondary to Reduced-Dose Cyclophosphamide. <i>Int J Radiat Oncol Biol Phys.</i> 2019; <b>103</b>(5): 1151–7. <a target=xrefwindow id=d10319e2128 href="http://www.ncbi.nlm.nih.gov/pubmed/30508617">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2131 href="https://doi.org/10.1016/j.ijrobp.2018.11.049">Publisher Full Text </a> | <a target=xrefwindow id=d10319e2134 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6441953">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734599168">Faculty Opinions Recommendation</a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d10319e2147 class=n-a></a>Lucas JT, Pappo AS, Wu J, <i> et al.</i>: Excessive Treatment Failures in Patients With Parameningeal Rhabdomyosarcoma With Reduced-dose Cyclophosphamide and Delayed Radiotherapy. <i>J Pediatr Hematol Oncol.</i> 2018; <b>40</b>(5): 387–90. <a target=xrefwindow id=d10319e2158 href="http://www.ncbi.nlm.nih.gov/pubmed/29683960">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2161 href="https://doi.org/10.1097/MPH.0000000000001188">Publisher Full Text </a> | <a target=xrefwindow id=d10319e2165 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6520047">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d10319e2174 class=n-a></a>Weigel BJ, Lyden E, Anderson JR, <i> et al.</i>: Intensive Multiagent Therapy, Including Dose-Compressed Cycles of Ifosfamide/Etoposide and Vincristine/Doxorubicin/Cyclophosphamide, Irinotecan, and Radiation, in Patients With High-Risk Rhabdomyosarcoma: A Report From the Children's Oncology Group. <i>J Clin Oncol.</i> 2016; <b>34</b>(2): 117–22. <a target=xrefwindow id=d10319e2185 href="http://www.ncbi.nlm.nih.gov/pubmed/26503200">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2188 href="https://doi.org/10.1200/JCO.2015.63.4048">Publisher Full Text </a> | <a target=xrefwindow id=d10319e2192 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5070550">Free Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/734276770"><span class="faculty-opinion-icon small"></span></a><a name=d10319e2202 class=n-a></a>Malempati S, Weigel BJ, Chi YY, <i> et al.</i>: The addition of cixutumumab or temozolomide to intensive multiagent chemotherapy is feasible but does not improve outcome for patients with metastatic rhabdomyosarcoma: A report from the Children’s Oncology Group. <i>Cancer.</i> 2019; <b>125</b>(2): 290–7. <a target=xrefwindow id=d10319e2213 href="http://www.ncbi.nlm.nih.gov/pubmed/30351457">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2216 href="https://doi.org/10.1002/cncr.31770">Publisher Full Text </a> | <a target=xrefwindow id=d10319e2220 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6329653">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/734276770">Faculty Opinions Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/727835653"><span class="faculty-opinion-icon small"></span></a><a name=d10319e2233 class=n-a></a>Chisholm JC, Merks JHM, Casanova M, <i> et al.</i>: Open-label, multicentre, randomised, phase II study of the EpSSG and the ITCC evaluating the addition of bevacizumab to chemotherapy in childhood and adolescent patients with metastatic soft tissue sarcoma (the BERNIE study). <i>Eur J Cancer.</i> 2017; <b>83</b>: 177–84. <a target=xrefwindow id=d10319e2244 href="http://www.ncbi.nlm.nih.gov/pubmed/28738258">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2247 href="https://doi.org/10.1016/j.ejca.2017.06.015">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/727835653">Faculty Opinions Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736963166"><span class="faculty-opinion-icon small"></span></a><a name=d10319e2260 class=n-a></a>Vaarwerk B, Mallebranche C, Affinita MC, <i> et al.</i>: Is surveillance imaging in pediatric patients treated for localized rhabdomyosarcoma useful? The European experience. <i>Cancer.</i> 2019; <b>126</b>(4): 823–31. <a target=xrefwindow id=d10319e2271 href="http://www.ncbi.nlm.nih.gov/pubmed/31750944">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2274 href="https://doi.org/10.1002/cncr.32603">Publisher Full Text </a> | <a target=xrefwindow id=d10319e2278 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7027831">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736963166">Faculty Opinions Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/737141692"><span class="faculty-opinion-icon small"></span></a><a name=d10319e2291 class=n-a></a>Compostella A, Affinita MC, Casanova M, <i> et al.</i>: Topotecan/carboplatin regimen for refractory/recurrent rhabdomyosarcoma in children: Report from the AIEOP Soft Tissue Sarcoma Committee. <i>Tumori.</i> 2019; <b>105</b>(2): 138–43. <a target=xrefwindow id=d10319e2302 href="https://doi.org/10.1177/0300891618792479">Publisher Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/737141692">Faculty Opinions Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735730536"><span class="faculty-opinion-icon small"></span></a><a name=d10319e2315 class=n-a></a>Mascarenhas L, Lyden ER, Breitfeld PP, <i> et al.</i>: Risk-based treatment for patients with first relapse or progression of rhabdomyosarcoma: A report from the Children's Oncology Group. <i>Cancer.</i> 2019; <b>121</b>(15): 2602–2609. <a target=xrefwindow id=d10319e2326 href="http://www.ncbi.nlm.nih.gov/pubmed/31067356">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2329 href="https://doi.org/10.1002/cncr.32122">Publisher Full Text </a> | <a target=xrefwindow id=d10319e2333 href="http://www.ncbi.nlm.nih.gov/pmc/articles/7069123">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735730536">Faculty Opinions Recommendation</a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/736596348"><span class="faculty-opinion-icon small"></span></a><a name=d10319e2346 class=n-a></a>Mascarenhas L, Chi Y-Y, Hingorani P, <i> et al.</i>: Randomized Phase II Trial of Bevacizumab or Temsirolimus in Combination With Chemotherapy for First Relapse Rhabdomyosarcoma: A Report From the Children's Oncology Group. <i>J Clin Oncol.</i> 2019; <b>37</b>(31): 2866–74. <a target=xrefwindow id=d10319e2357 href="http://www.ncbi.nlm.nih.gov/pubmed/31513481">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2360 href="https://doi.org/10.1200/JCO.19.00576">Publisher Full Text </a> | <a target=xrefwindow id=d10319e2364 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6823886">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/736596348">Faculty Opinions Recommendation</a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d10319e2378 class=n-a></a>Briggs JW, Ren L, Chakrabarti KR, <i> et al.</i>: Activation of the unfolded protein response in sarcoma cells treated with rapamycin or temsirolimus. <i>PLoS One.</i> 2017; <b>12</b>(19): e0185089. <a target=xrefwindow id=d10319e2389 href="http://www.ncbi.nlm.nih.gov/pubmed/28926611">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2392 href="https://doi.org/10.1371/journal.pone.0185089">Publisher Full Text </a> | <a target=xrefwindow id=d10319e2396 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5605117">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a target=_blank title="Faculty Opinions recommended" class="research-layout prime-recommended-reference" href="https://facultyopinions.com/prime/735608663"><span class="faculty-opinion-icon small"></span></a><a name=d10319e2405 class=n-a></a>Yan C, Brunson DC, Tang Q, <i> et al.</i>: Visualizing Engrafted Human Cancer and Therapy Responses in Immunodeficient Zebrafish. <i>Cell.</i> 2019; <b>177</b>(7): 1903–1914.e14. <a target=xrefwindow id=d10319e2416 href="http://www.ncbi.nlm.nih.gov/pubmed/31031007">PubMed Abstract </a> | <a target=xrefwindow id=d10319e2419 href="https://doi.org/10.1016/j.cell.2019.04.004">Publisher Full Text </a> | <a target=xrefwindow id=d10319e2423 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6570580">Free Full Text </a> | <a target=_blank title="Faculty Opinions recommended" href="https://facultyopinions.com/prime/735608663">Faculty Opinions Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 08 Jul 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-685&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-685&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA<br/> <p> <div class=margin-bottom> Jessica Gartrell <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> <div class=margin-bottom> Alberto Pappo <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/9-685/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 08 Jul 2020, 9:685 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.22451.1">https://doi.org/10.12688/f1000research.22451.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2020 Gartrell J and Pappo A. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=24777 data-id=22451 data-downloads="" data-views="" data-scholar="10.12688/f1000research.22451.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/9-685/v1/pdf?article_uuid=9edfe0dd-64ee-41f3-88bf-a03a8493c1de" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.22451.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Gartrell J and Pappo A. Recent advances in understanding and managing pediatric rhabdomyosarcoma [version 1; peer review: 3 approved] <i>F1000Research</i> 2020, <b>9</b>(Faculty Rev):685 (<a href="https://doi.org/10.12688/f1000research.22451.1" target=_blank>https://doi.org/10.12688/f1000research.22451.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=22451 id=mobile-track-article-signin-22451 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/22451?target=/articles/9-685"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=24777 /> <input name=articleId type=hidden value=22451 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Daniel Orbach</strong>, SIREDO oncology center (Care, Innovation and Research for Children, Adolescents and Young Adults with cancer), Institut Curie, PSL university, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Leo Mascarenhas</strong>, Cancer and Blood Disease Institute, Children’s Hospital Los Angeles, Department of Pediatrics, Keck School of Medicine, University of Southern California, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> LM is a member of soft tissue sarcoma committee of the Children’s Oncology Group. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Sarah Donaldson</strong>, Department of Radiation Oncology, Stanford University School of Medicine, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 08 Jul 2020</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/9-685&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/9-685&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=64354-66053></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=70790-66052></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=70791-66054></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/9-685/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>08 Jul 20</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Daniel Orbach</strong>, SIREDO oncology center (Care, Innovation and Research for Children, Adolescents and Young Adults with cancer), Institut Curie, PSL university, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Leo Mascarenhas</strong>, Cancer and Blood Disease Institute, Children’s Hospital Los Angeles, Department of Pediatrics, Keck School of Medicine, University of Southern California, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> LM is a member of soft tissue sarcoma committee of the Children’s Oncology Group. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Sarah Donaldson</strong>, Department of Radiation Oncology, Stanford University School of Medicine, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/9-685&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/9-685/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in understanding and managing...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/9-685/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/9-685/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/9-685/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Gartrell J and Pappo A');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/9-685/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/9-685",
            templates : {
                twitter : "Recent advances in understanding and managing pediatric rhabdomyosarcoma. Gartrell J and Pappo A, published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/9-685/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in understanding and managing pediatric rhabdomyosarcoma", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in understanding and managing pediatric rhabdomyosarcoma", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/22451/24777")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "24777");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "66053": 1,
                           "66052": 1,
                           "66054": 1,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "310a0200-2190-4ac6-9207-65d3e98a982b";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-685.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-685.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/9-685.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/9-685.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/9-685.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>